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ABSTRACT
Objective Left ventricular remodelling following a ST-
segment elevated myocardial infarction (STEMI) is an 
adaptive response to maintain the cardiac output despite 
myocardial tissue loss. Limited studies have evaluated 
long term ventricular function using cardiac magnetic 
resonance imaging (CMR) after STEMI.
Methods Study population consisted of 155 primary 
percutaneous coronary intervention treated first STEMI 
patients. CMR was performed at 4±2 days, 4 months 
and 24 months follow-up. Patients were treated with 
beta-blockers, ACE-inhibitors or AT-II- inhibitors, statins 
and dual antiplatelet according to current international 
guidelines.
Results Mean left ventricular ejection fraction (LVEF) 
at baseline was 44%±8%. Twenty-one per cent of the 
study population had an increase of more than 5.0% 
after 4 months of follow-up and 21% of the cohort had a 
decrease of more than 5.0%. Patients with long-term LVEF 
deterioration have significantly larger end-systolic volumes 
than patients with improvement of LVEF (61±23 mL/
m2 compared with 52±21 mL/m2, p=0.02) and less 
wall thickening in the remote zone. Patients with LVEF 
improvement had significantly greater improvement in wall 
thickening in the infarct areas and in the non-infarct or 
remote zone.
Conclusion Contrary to previous studies, we demonstrate 
that myocardial remodelling after STEMI is a long-term 
process. Long-term LVEF deterioration is characterised by 
an increase in end-systolic volume and less wall thickening 
in the remote zones. Patients with LVEF improvement 
exhibit an increase in left ventricular wall thickening both in 
the infarct as well as in the remote zones.
Trial registration The HEBE study is registered in The 
Netherlands Trial Register #NTR166 (www. trialregister. 
nl) and the International Standard Randomised Controlled 
Trial, #ISRCTN95796863 (https:// c- d- qn9pqajji. sec. amc. 
nl).
INTRODUCTION
Left ventricular remodelling after ST-segment 
elevation myocardial infarction (STEMI) 
treated with primary percutaneous coronary 
intervention is a major determinant for the 
short-term and long-term clinical outcomes.1 
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KEY QUESTIONS
What is already known about this subject?
Adverse left ventricular (LV) remodelling after 
revascularisation for ST-segment elevation myocardial 
infarction (STEMI) is a major determinant for the 
short-term and long-term clinical outcomes. When 
remodelling occurs, the entire heart can be involved, 
as disproportionate thinning and dilation in the infarct 
region (ie, infarct expansion) is accompanied by a 
distortion in shape of the entire heart with volume-
overload hypertrophy of the non-infarcted myocardium.
What does this study add?
The results of the current study show that LV 
remodelling, both positive and negative, is an ongoing 
process and continues at least up to 2 years after 
STEMI, involving the infarct zone and remote zones. 
Long-term left ventricular ejection fraction (LVEF) 
deterioration is characterised by an increase in end-
systolic volume and less wall thickening in the remote 
zones. Patients with long-term LVEF improvement 
exhibit an increase in left ventricular wall thickening 
both in the transmural infarct and remote zones.
How might this impact on clinical practice?
This study points out that monitoring and treatment 
of adverse LV remodelling after acute myocardial 
infarction should be performed up to at least 2 years of 
follow-up. Furthermore, our findings suggest that the 
defined cut of value for myocardium viability (75% 
transmurality as assessed by CMR) is questionable 
as the infarct zone exhibits improvement at long-
term follow-up. To conclude, despite the fact that 
early remodelling may initially seem adaptive with 
early maintenance of cardiac output, this continuous 
remodelling process may only further deteriorate the 
LV with increased LV volumes and increased incidence 
of heart failure and cardiovascular death.
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Adverse left ventricular remodelling refers to alterations 
in ventricular architecture involving both the infarcted 
and non-infarcted zones leading to progressive increase 
in systolic and diastolic left ventricular volumes.2–4 Cardiac 
magnetic resonance (CMR) has emerged as the gold 
standard for assessing the functional and morphological 
changes of the left ventricle.4 To date, there is limited CMR 
data assessing long-term left ventricular function and the 
long-term LV remodelling process after STEMI. Especially, 
there is limited data regarding LV function changes after 
the initial months. The purpose of this study was to evaluate 
the early (baseline–4 months) and late remodelling process 
(4–24 months) assessed by CMR. Moreover, segmental 
CMR analysis was used to provide more insight in the LV 
remodelling process.
METHODS
Study population
The study population consisted of patients with STEMI 
included in the HEBE study, which is a multicentre, 
randomised trial assessing intracoronary bone marrow 
cell therapy (#ISRCTN95796863 and #NTR166). This 
study is a CMR subanalysis of this trial. The details of the 
design and results have been published previously.5 CMR 
imaging was performed at baseline, 4 months and 2 years 
of follow-up. In summary, patients 30–75 years of age were 
eligible for inclusion if they met the following inclusion 
criteria: successful percutaneous coronary intervention 
within 12 hours after onset of symptoms, three or more 
hypokinetic or akinetic left ventricular (LV) segments 
observed on echocardiography performed at least 12 hours 
after percutaneous coronary intervention, and an eleva-
tion of creatine kinase (CK) or creatine kinase myocardial 
band (CK-MB)more than 10 times the local upper limit 
of normal (ULN). Patients with a previous myocardial 
infarction were not included in this study. There were no 
significant differences between the two treatment groups 
and the control group at baseline.5 All patients were 
treated with primary PCI (PPCI) with stent implantation 
within 12 hours of symptom onset. Patients were treated 
with aspirin, heparin and a P2Y12 inhibitor according to 
American College of Cardiology/American Heart Associa-
tion practice guidelines.
Of the 200 patients that originally enrolled in the HEBE 
study, at 24 months, one had withdrawn informed consent, 
three had died, three did not consent to this additional 
long-term follow-up and three were lost to follow-up. At 
24 months, 19 patients had clinical follow-up but did not 
undergo CMR because of implantable cardioverter-de-
fibrillator implantation (n=8), pacemaker implantation 
(n=1) or because they refused (n=10). Additionally, 12 
patients were excluded from core lab analysis due to one 
of the following reasons: poor quality due to breathing or 
triggering artefacts, or baseline, 4 months and 24 months 
could not be matched. Of the remaining 159 patients, 
four patients had a recurrent myocardial infarction in 
the 2 years of follow-up and were also excluded from the 
analysis.
Cardiac magnetic resonance imaging
Patients were studied on the same clinical magnetic 
resonance scanner system for the consecutive studies 
(Siemens 1.5T, Erlangen, Germany; Philips 1.5T and 
3.0T, Best, the Netherlands; GE Healthcare1.5T, Buck-
inghamshire, UK). The CMR protocol at 24 months was 
similar to the CMR protocol at baseline and 4 months, 
with the exception that no contrast medium was admin-
istrated to assess size and extent of infarction. At baseline 
and at 4 months' delayed enhancement (DE) was done 
10–15 min after administration of a gadolinium-based 
contrast agent (Dotarem, Guerbet, Roissy, France; 
0.2 mmol/kg) with a two-dimensional segmented inver-
sion recovery gradient-echo pulse sequences. Typical 
in-plane resolution was 1.4×1.7 mm2, with a slice thickness 
of 5.0–6.0 mm (repetition time/echo time=9.6/4.4/4.4 
ms, flip angle 25°, triggering to every other heartbeat). 
Inversion time was set to null the signal of viable myocar-
dium.
Moreover, contiguous short axis slices were acquired 
every 10 mm covering the whole left ventricle using a 
cine retrospectively ECG-gated segmented steady-state 
free precession pulse sequence, with image parameters 
identical to the baseline and 4 months follow-up scan. 
Left ventricle (LV) volumes and mass were measured 
on the cine images and indexed for body-surface area. 
Left ventricular ejection fraction (LVEF) was calculated 
following assessment of left ventricle end-diastolic volume 
(LVEDV) and left ventricle end-systolic volume (LVESV).
For analysis of regional myocardial function, each short 
axis slice was divided in 12 equiangular segments to calcu-
late wall thickening (in mm) of each segment by subtracting 
end-diastolic from end-systolic wall thickness. Segmental 
wall thickness was measured at end-systole and end-diastole 
after manual tracing of endocardial and epicardial borders 
in stop-frame images, excluding trabeculations and papil-
lary muscles. The contours were drawn blinded to patient 
identity, clinical history and scan time point. Segmental 
wall thickness was calculated as the average of the chords 
within one segment. Segmental wall thickening (SWT) in 
millimetres was calculated as: end-systolic wall thickness 
minus end-diastolic wall thickness.
All CMR analyses were performed in a core laboratory 
by two experienced technicians using a standardised 
protocol, and analyses were supervised by a third 
reader with >10 years of CMR experience. They were 
all blinded to treatment allocation. Both baseline and 
4-month follow-up scan were used to match all three 
CMR imaging for slice position using anatomic land-
marks, such as papillary muscles and right ventricular 
insertion sites to have consistent comparison between 
the acquisitions. The CMR data were analysed using a 
dedicated software package (Mass, Medis, Leiden, The 
Netherlands).
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Statistical analysis
Categorical data are presented as frequencies 
(percentage) and continuous data as mean±SD. The 
study population was divided in a group with LVEF 
improvement and LVEF deterioration. LVEF improve-
ment was defined as any increase of LVEF between 
baseline and 4 months and 4 months and 24 months. 
LVEF deterioration was defined as no improvement of 
LVEF, or a decrease in LVEF between two sequential CMR 
imaging time points. Unpaired Student’s t-test and a Fish-
er’s exact test were used to compare differences between 
groups of continuous and categorical variables, respec-
tively. To account for non-independence of the data, we 
used multilevel logistic regression to analyse the relation 
between wall thickening and improvement of LVEF. In 
the multivariate analysis, treatment as randomised in the 
HEBE trial was always entered as a covariate. We used two 
levels (segments clustered within patients). All p values 
are two sided, and statistical significance was set at p<0.05. 
Statistical analysis was done with the Statistical Package 
for Social Sciences software (SPSS V.21.0 for Windows).
RESULTS
The final study population consisted of 155 patients, 
with an average age of 56 years. The majority of the study 
population was male, namely 85%. Also, more than half 
of the patients had an anterior infarction (63%). Mean 
LVEF at baseline was 44%±8%, at 4 months 48%±9% and 
at 2 year follow-up 48%±9%. Infarct size at baseline was 
22±12 g. Microvascular obstruction was present in 58% 
of the patients (table 1). There was a systematic use of 
secondary prevention treatment with beta-blockers and 
ACE-inhibitors. At discharge, 95% of the study popula-
tion received ACE-inhibitors or angiotensin II receptor 
antagonist and 94% beta-blockers (table 1). During the 
initial 4 months we observed a mean LVEF increase of 
4±7%.
Late remodelling (4–24 months)
Between 4 months and 24 months of follow-up there was 
no LVEF change for the entire population (0%±7%). 
Twenty-one per cent of the study population had an 
increase of more than 5.0% after 4 months of follow-up 
and 21% of the cohort had a decrease of more than 
5.0%. Table 2 displays the CMR parameters split for 
patients with LVEF improvement (n=78) versus patients 
with LVEF deterioration (n=77) between 4 and 24 
months of follow-up. Patients with LVEF deterioration 
had a significantly larger LVESV at 24 months compared 
with the group with LVEF improvement (61±23 mL/m2 
compared with 52±21 mL/m2, p=0.02), without differ-
ences in LVEDV. No difference in baseline infarct size 
was observed in patients who had LVEF improvement 
versus patients with LVEF deterioration (21±13 vs 22±12, 
p=0.62). There was also no difference in microvascular 
obstruction (54% vs 63%, p=0.33). There was no differ-
ence in medication use at 4 months (table 2). However, 
patients with LVEF deterioration more frequently did 
not use beta-blockers at 24 months (20% vs 4%, p=0.004) 
Table 1 Baseline characteristics for study population
n=155
Age (years) 56±9
Male gender 132 (85%)
Diabetes mellitus 9 (6%)
Known hypertension 47 (30%)
Hypercholesterolaemia 29 (19%)
Current cigarette smoking 79 (51%)
Time from symptom onset to PCI (hours)* 3.3 (2.2–4.5)
Anterior infarction 98 (63%)
Medication at discharge
  ACE-inhibitors/ATII antagonists 147 (95%)
  Beta-blockers 146 (94%)
Cardiac magnetic resonance imaging
  LVEF (%) 44±8
  End-diastolic volume (mL/m2) 98±16
  End-systolic volume (mL/m2) 56±14
  Infarct size (g)† 22±12
  Presence of microvascular obstruction 90 (58%)
*Median (25th–75th percentile).
†Analysis available in 132 patients.
AT, angiotensin; LVEF, left ventricular ejection fraction; PCI, 
percutaneous coronary intervention. 
Table 2 Cardiac magnetic resonance imaging parameters 
for study population split for change in left ventricular 
ejection fraction between 4 months and 24 months
LVEF 
improvement
(n=78)
LVEF 
deterioration
(n=77) p Value
LVEF (%)
  At 3–5 days 45±9 43±8 0.07
  4 months 46±8 50±9 0.007
  24 months 51±9 44±8 0.001
LVEDV (mL/m2)
  3–5 days 98±16 98±15 0.85
  4 months 104±22 104±22 0.96
  24 months 104±26 107±25 0.47
LVESV (mL/m2)
  3–5 days 57±14 57±14 0.30
  4 months 57±14 54±15 0.27
  24 months 52±21 61±23 0.02
Infarct size (g)‡ at 
3–5 days
21±13 22±12 0.62
Presence of MVO at 
3–5 days
42 (54%) 48 (63%) 0.33
LVEF, left ventricular ejection fraction (%); LVEDV, left ventricular 
end-diastolic volume; LVESV, left ventricular end-systolic volume; 
MVO, microvascular obstruction.
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(table 3). When comparing the clinical outcomes in the 
5-year follow-up of the two patient groups, there were 
no significant differences in New York Heart Association 
classification, occurrence of heart failure, repeat PCI, 
recurrent myocardial infarction and mortality.
SWT and remodelling
Segmental CMR analysis was used to gain more insight 
in the long-term remodelling process. Improvement 
in wall thickening (in mm) between 24 months and 
4 months of follow-up was used to assess differences of 
infarct transmurality and subsequent positive or adverse 
LVEF changes. Therefore, in segmental CMR analysis, 
we assessed absolute wall thickening in millimetre per 
segment and categorised these segments according to 
the extent of transmurality (percentage DE). Change in 
wall thickening (mm) was significantly greater in patients 
with LVEF improvement compared with patients with 
LVEF deterioration (figure 1). Particularly, in segments 
with 0% or 1%–25% DE, the remote zone, this change in 
wall thickening was larger in patients with LVEF improve-
ment compared with patients with LVEF deterioration.
DISCUSSION
The present study assesses the long-term functional 
outcome of patients with STEMI treated with primary 
PCI. There was a systematic use of secondary preven-
tion treatment with beta-blockers and ACE inhibition 
to slow, or reverse cardiac remodelling after acute 
myocardial infarction.6–18 The main findings can be 
summarised as follows: (1) left ventricular function 
improvement after acute myocardial infarction is an 
ongoing process continuing up to 2 years follow-up, 
(2) long-term LVEF deterioration is characterised by 
an increase in end-systolic volume and less wall thick-
ening in the remote zones, (3) patients with long-term 
LVEF improvement exhibit an increase in left ventric-
ular wall thickening both in the transmural infarct and 
remote zones.
Left ventricular function improvement after acute 
myocardial infarction is a dynamic process continuing after 
4 months of follow-up
This increase of LV volumes in the process of LV 
remodelling can be considered adaptive as it is an 
attempt to augment stroke volume and to maintain 
cardiac output. However, in patients with progressive 
postinfarction dilation, the end-systolic volume index 
increases progressively and LVEF declines. These 
changes are important predictors of mortality.19 20 
Table 3 Follow-up of clinical outcomes and medication 
use until 5 years for study population split for change in 
left ventricular ejection fraction between 4 months and 24 
months
LVEF 
improvement 
(n=78%)
LVEF 
deterioration
 (n=77%) p Value
Medication at 4 months
  ACE-inhibitors/ATII 
antagonists 
72 (92) 69 (90) 0.32
  Beta-blockers 72 (92) 69 (90) 0.56
Medication at 2 years
  ACE-inhibitors/ATII 
antagonists 
73 (94) 67 (87) 0.35
  Beta-blockers 75 (96) 61 (80) 0.004
NYHA class I 
  4 months 63 (81) 66 (86) 0.41
  2 years 64 (82) 70 (92) 0.06
Hospitalisation for heart failure
  2 years 1 (1) 2 (3) 0.56
  5 years 3 (4) 1 (1) 0.56
Repeat PCI
  2 years 17 (21) 16 (21) 0.88
  5 years 18 (23) 18 (23) 1.00
CABG
  2 years 0 (0) 0 (0) 1.00
Recurrent myocardial infarction*
  5 years 1 (1.3) 3 (4) 0.31
Mortality*
  5 years 3 (4) 1 (1) 0.31
*Patients who died (n=3) or suffered recurrent myocardial infarction 
(n=4) in the first 24 months after PCI were not included in this 
substudy.
AT, angiotensin; CABG, coronary artery bypass grafting; NYHA, 
New York Heart Association; PCI, percutaneous coronary 
intervention.
Figure 1 Change in wall thickening (in mm) between 24 
and 4 months follow-up as assessed by cardiac magnetic 
resonance imaging categorised for percentage of delayed 
enhancement and split for patients with LVEF improvement 
or deterioration. LVEF, – left ventricular ejection fraction; 
DE, delayed enhancement.
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There is accumulating evidence that left ventricular 
remodelling is a dynamic process occurring in the first 
weeks21 and months22–24 after myocardial infarction and 
in the long period thereafter.25–29 We demonstrated 
that left ventricular remodelling is a long-term process 
and is observed in the period between 4 and 24 
months after STEMI. In the current study, remodel-
ling was not influenced by secondary ischaemic events, 
as these patients were excluded from the analysis. To 
our knowledge, there are no other CMR studies that 
report the occurrence of long-term remodelling at 
2 years. The magnitude of adverse remodelling at 4 
months is related to infarct size and the presence of 
microvascular injury. In the current study, no differ-
ence in infarct size was observed in patients who 
developed deterioration in LVEF between 4 and 24 
months. However, as previous studies demonstrated, 
infarct size and the presence of microvascular injury at 
baseline are associated with left ventricular function at 
4 months following myocardial infarction.30–32
Long-term LVEF deterioration is characterised by an 
increase in end-systolic volume and less wall thickening in 
the remote zones
LVESV was significantly increased in patients with LVEF 
deterioration. In a prior study, LVESV has been reported 
as the strongest prognostic indicator for survival in post-
STEMI patients.33 End-systolic volume is influenced by 
both end-diastolic volume and myocardial contraction. 
Impairment in LV function after an acute MI is induced 
by myocardial tissue necrosis in the infarct-related 
myocardium and by remote myocardial dysfunction.21 34 
The remote myocardial dysfunction may explain why an 
AMI often exhibits a larger functional loss than expected 
solely on the basis of the extent of myocardial necrosis. 
Bogeart et al evaluated regional morphology and function 
in patients in their first week after having a reperfused 
anterior myocardial infarction.21 They demonstrated 
that changes in LV morphology and shape are found 
in the infarcted, adjacent and remote regions. The 
authors postulated that remote myocardial dysfunction 
is primarily caused by an impairment in the longitu-
dinal and circumferential strains.35 Remote myocardial 
dysfunction could therefore be seen as secondary to 
morphological changes in the infarct region, leading 
to an increased systolic longitudinal wall stress. It has 
also been postulated that potential mechanisms for the 
initial decrease in wall thickening in remote and adjacent 
segments are coronary vasodilator abnormalities in the 
non-occluded arteries. Rademakers et al confirmed this 
phenomena describing it as an increase in loading condi-
tion of the adjacent myocardium.36 Other possible causes 
of decreased performance beside changes in load levels 
could relate to decreased intrinsic contractility, secondary 
to perfusion abnormalities at the microcirculatory level, 
possibly induced by overstimulation by catecholamines, 
inflammatory changes, altered regional neuro-adren-
ergic drive, and so on. Some of these mechanism are 
more likely to be at work in the infarct and adjacent 
regions, but they could also influence the remote zones. 
Of course, deterioration of the remote myocardium 
might not also be due to remodelling; instead chronic 
ischaemia resulting in hibernation can be the underlying 
cause.37 38 A functional assessment to exclude ischaemia 
may be essential to rule out this possibility.
Patients with long-term LVEF improvement exhibit an 
increase in left ventricular wall thickening both in the 
transmural infarct and remote zones
In animal models, there is an early increase in wall 
thickening in remote myocardial segments during the 
first weeks after reperfusion.6 The early increase in wall 
thickening as assessed by CMR in 22 patients with reper-
fused first-time MI confirmed these results.25 The authors 
found that the adjacent segments were found to recover 
primairly between 1 and 6 weeks after infarction. We 
confirmed these results in a larger population and with 
longer follow-up.
In summary, it has been suggested that the long-term 
remodelling process is driven by hypertrophic myocyte 
elongation in the non-infarcted zone, resulting in 
increase in wall mass and left ventricle enlargement. This 
is accompanied by a shift from an elliptical to a more 
spherical chamber configuration.4 7 39–44 These changes, 
together with a decline in performance of the pathologi-
cally hypertrophied myocyte and interstitial fibrosis within 
the non-infarcted zone, results in progressive decline in 
ventricular performance.45–49 This is in accordance with 
the current findings. We observed with segmental CMR 
analysis that patients with LVEF deterioration between 
4 and 24 months follow-up had a significant decreased 
change in wall thickening (mm) compared with patients 
with LVEF improvement. Choi et al demonstrated that 
the transmural extent of infarction as defined by CMR 
predicts improvement in contractile function.24 We 
observed that these changes in wall thickening were 
observed both in the segments with transmural infarc-
tion (DE 76%–100%) and in the non-infarct or remote 
zone (DE 0% and DE 1%–25%). Moreover, the observed 
change in wall thickening in patients with LVEF improve-
ment or deterioration was not dependent on infarct 
size and was similar in both groups. Patients showing 
LVEF improvement showed a significant increased wall 
thickening in the transmural segments compared with 
patients with LVEF deterioration. This may suggest that 
the defined cut of value for viability (75% transmurality 
as assessed by CMR) is questionable and needs more 
research as the infarct zone exhibits improvement at 
long-term follow-up.
Thus, the results of the current study show that LV 
remodelling, both positive and negative, is an ongoing 
process and continues at least up to 2 years after STEMI, 
involving the infarct zone and remote zones. Despite the 
fact that early remodelling may initially seem adaptive 
with early maintenance of cardiac output, this continuous 
remodelling process may only further deteriorate the LV 
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with increased LV volumes and increased incidence of 
heart failure and cardiovascular death.
Limitations
In the current study, patients with relatively large infarcts 
(elevation of creatine kinase-myocardial band >10 times 
the ULN) were included. Therefore, the occurrence 
of adverse remodelling is likely higher than in a more 
general acute MI population. Patients who died (n=3) or 
received ICD (n=8) were excluded from this CMR anal-
ysis; these patients might represent the patients with the 
most extensive adverse remodelling. Also, we have no 
CMR data between 4 months and 24 months of follow-up. 
It is possible that the remodelling process continued for 
6 or 12 months but then stopped. Lastly, in the current 
study, the remodelling process was only assessed by 
functional parameters assessed by CMR. Despite its clin-
ical and prognostic importance, we do not provide any 
additional insights on the remodelling process at the 
histological level.
CONCLUSION
Cardiac remodelling is a dynamic and ongoing process 
up to 24 months following acute myocardial infarction. 
Long-term LVEF deterioration is characterised by an 
increase in end-systolic volume and less wall thickening 
in the remote zones. Patients with LVEF improvement 
exhibit an increase in left ventricular wall thickening 
both in the infarct as well as in the remote zones.
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